Total Funding
63
41
Total FundingPost-IPO Equity raised
Growth Score
3 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
35773
NKGen Biotech is restoring immune function through the development of unique natural killer (NK) cell therapies for the treatment of cancer.
- Paul Y. Song: Chief Executive Officer
- James Graf: Interim Chief Financial OfficerPast Role: Graf Industrial, Chief Executive Officer and Co-founder
NKMAX
About the Company
NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. Leveraging proprietary cell expansion and activation technologies along with cutting-edge cell manufacturing expertise, NKGen Biotech has the ability
to infinitely expand natural killer cells while significantly enhancing cytotoxicity.
